Firefly Neuroscience, Inc. (NASDAQ: AIFF) shares rocketed Thursday, on announcing a partnership with the Department of War to support the assessment and treatment of active-duty U.S. service members and veterans suffering from Post-Traumatic Stress Disorder and/or Traumatic Brain Injury.
The genesis of this innovative public-private brain health partnership was initial work by the founders of Evoke Neuroscience, Inc. (acquired by Firefly in May 2025) with the U.S. Naval Medical Center Camp Lejeune Family Medicine Residency program. Specific details of the partnership and related programs remain confidential in accordance with applicable agreements.
PTSD and TBI represent two of the most significant and pervasive health challenges facing the U.S. military. The total excess economic burden of PTSD in the United States has been estimated at $232.2 billion, of which approximately $42.7 billion is attributed directly to the military population.
In contrast to PTSD, the incidence of TBI is higher among military than civilian populations, in part because of the physical demands of military service and the potentially dangerous activities associated with military operations and training. According to the RAND Corporation, more than 444,300 U.S. service members were diagnosed with at least one TBI between 2000 and 2021.
“Despite the scale of this public and military health burden,” read this morning’s news release, “objective, biomarker-driven diagnostic tools have remained largely absent from standard care — a gap that Firefly’s EEG/ERP technology is intended to help address.”
AIFF shares hiked 62 cents, or 36.9%, to $2.34.
Related Stories
